ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor.
 PMID: 16611347       2006       American journal of transplantation
Abstract: De novo HBV infection developed more than 3 years after LT with a lamivudine-resistant polymerase mutant containing the rtM204I and rtl180L/M mutations.


  Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
 PMID: 16618409       2006       Gastroenterology
Abstract: RFMP exploits differences in molecular masses between wild-type and variant bases of rtM204V/I following PCR amplification of HBV DNA with a lower limit of detection being 100 copies/mL.


  Antiviral drug resistance: clinical consequences and molecular aspects.
 PMID: 16673294       2006       Seminars in liver disease
Abstract: The rtM204I/V is selected by lamivudine and L-nucleosides.


  Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
 PMID: 16789011       2006       Journal of medical virology
Abstract: Changes in rtM204I and rtL180M viral loads were greater than that of the rtM204V, albeit statistically insignificant.
Abstract: Moreover, the greatest change in viral load was seen for rtM204I without hepatitis B e antigen (HBeAg).
Abstract: We conclude that the rtM204I may be more sensitive to ADV in vivo.


  Mutations in surface and polymerase gene of chronic hepatitis B patients with coexisting HBsAg and anti-HBs.
 PMID: 16830379       2006       World journal of gastroenterology
Abstract: Lamivudine (LMV)-selected mutations were found in three patients who developed anti-HBs, which occurred in amino acid positions (196, 198, 199) of the surface protein and in YMDD motif (M204I/V) of the polymerase protein simultaneously.


  The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
 PMID: 16856618       2006       Antiviral therapy
Abstract: Cumulative viral breakthrough rates at 3 years was 75.0% and 14.3% in patients who had the rtM204I mutant and wild-type virus at 3 months, respectively (P=0.002).


  Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
 PMID: 16871563       2006       Hepatology (Baltimore, Md.)
Abstract: Lamivudine-associated mutations (rtV173L, rtL180M, rtM204V/I) could be detected in 6 patients at baseline of TDF, but this obviously did not influence the response.


  Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment.
 PMID: 16981258       2006       World journal of gastroenterology
Abstract: Primer specific to rtM204I with an additional 3'-penultimate base mismatched to both the mutant and wild-type sequence was selected for YIDD detection.


  Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
 PMID: 15655050       2005       Journal of viral hepatitis
Abstract: Four major patterns of lamivudine-resistant HBV were identified: rtL180M + rtM204V (60%), rtV173L + rtL180M + rtM204V (19%), rtM204I (9%) and rtL180M + rtM204I (9%).
Abstract: In addition to the rtM204V/I and the rtL180M mutations, the mutation


  Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
 PMID: 15720530       2005       Journal of viral hepatitis
Abstract: In most cases, wild-type HBV was mutated with the substitution of only rtM204I at first, and rtL180M/M204I mutations and then rtL180M/M204V mutations subsequently appeared.



Browser Board

 Co-occurred Entities




   Filtrator